INTRODUCTION
Glycidol fatty acid esters (GEs; Fig.1 ) are by-products of the general process of deodorization during the production of fats and oils. European countries have raised the question of the safety of GEs found in refined edible oils. In March 2009, the German Federal Institute for Risk Assessment (BfR) issued an opinion on the risks conveyed by a known animal carcinogen, glycidol (G; Fig. 1 ) (Federal Institute for Risk Assessment, 2009) . In a worst case scenario, human infants that are exclusively fed commercial formula might take in harmful levels of G from the refined fat in the preparation if a bioavailable form was released fully by digestion. With no reliable analytical method to detect GEs in oils and little information on the conversion of GEs to G in the human body, BfR expressed the need for further research.
Extensive data on the toxicity and carcinogenicity of G are available. G is a known genotoxic carcinogen and is classified by the International Agency for Research on Cancer (IARC) as "probably carcinogenic to humans" (Group 2A) (IARC, 2000) . In contrast, little information relevant to toxicity is available on GEs. The IARC previously evaluated the human carcinogenicity of two GEs, glycidyl oleate and glycidyl stearate, and classified them as Group 3 (not classifiable) due to insufficient evidence (IARC, 1976a (IARC, , 1976b (IARC, and 1987 . Assessments of the health risk posed by GEs in foods will require toxicity and exposure data for G and GEs. A few in vivo kinetic studies of G using rodents have been reported (Jones, 1975; Nomeir Species differences in toxicokinetic parameters of glycidol after a single dose of glycidol or glycidol linoleate in rats and monkeys et al., 1995) . However, a search of the literature revealed no published in vivo kinetics studies of GEs, and in vitro metabolic studies are very limited (Boogaard et al., 1999) . It is assumed that GEs release G via lipase hydrolysis in the gut after ingestion. Whether GEs, if not entirely hydrolyzed, are absorbed and distributed to follow metabolic pathways similar to G is not clear (Habermeyer et al., 2011) . In the rat study using 14 C labeled-G, G appeared to be readily absorbed from the gastrointestinal tract following oral administration. In addition, G equivalents were excreted primarily in urine, secondarily in expired air and to a lesser extent in feces at 72 hr after administration (Nomeir et al., 1995) . In vivo and in vitro metabolic studies (Jones 1975; Patel et al., 1980) of G indicate that detoxification is achieved by conjugation with glutathione, partly mediated by glutathione S-transferase (GST). Alternatively, G can undergo enzymatic hydrolysis catalyzed by epoxide hydrolase (EH) or it may be hydrolyzed non-enzymatically to glycerol. Accordingly, the extent to which G is released from GEs and is detoxified can vary based on the gut environment and activities of the metabolic enzymes. Species differences between rodents and primates have been reported for these parameters. Therefore, human risk assessments of GEs are needed to clarify the toxicokinetics of GEs and G in rodent and primate models.
Diacylglycerol (DAG) oil is a unique edible oil containing > 80% (w/w) DAG that has shown a preventive effect on body fat accumulation. In June 2009, small amounts of GEs were found in DAG oil, and the levels were significantly higher than in other commercial edible oils. According to an analytical report by Masukawa et al. (2010) , GE levels in DAG oil were measured using five synthetic GE standards (palmitic, stearic, oleic, linoleic, and linolenic G-esters). The most common GE was glycidol linoleate (132 μg/g) followed by glycidol oleate (96 μg/g) with minor amounts (6.0 μg/g) of glycidol palmitate. Glycidol linoleate (9.0 μg/g) and glycidol oleate (10.2 μg/g) were identified as major GEs in one commercial edible oil that primarily consisted of triacylglycerol.
In the present study, the toxicokinetics of G and glycidol linoleate (GL), a primary GE found in DAG oil, were evaluated by measuring their levels in the plasma of male Crl:CD(SD) rats and cynomolgus monkeys collected at a specified time after a single exposure to the test substances.
MATERIALS AND METHODS

Chemicals
For animal experiments, glycidol linoleate (GL, purity 96.3 and 96.7%) was synthesized at Kao Corp. (Tokyo, Japan) (Masukawa et al., 2010) , and glycidol (G, purity 100.0%) was purchased from Kanto Chemical Co. Inc. (Tokyo, Japan). For analyses, GL (purity 94.3%) and G (purity 100.0%) standards were purchased from Wako Pure Chemical Industry, Ltd. (Tokyo, Japan). G heptadecanoic acid ester (purity 96%), synthesized by Kao Corp., was used as an internal standard (IS-1) for GL analysis. 2-Ethyl-1-hexanol (purity 99.9%), purchased from Wako Pure Chemical Industry, Ltd., was used as the internal standard (IS-2) for G analysis. HPLC-grade methanol, acetonitrile and 2-propanol (all from Wako Pure Chemical Industry, Ltd.) were used to prepare extracts from blood samples and for the LC-MS/MS mobile phase. Ultrapure water prepared using a Milli-Q Purification System (Millipore, Bedford, MA, USA) was used for the LC-MS/ MS mobile phase.
Animals
All animal experiments were conducted at Mitsubishi Chemical Medience Corp. (Ibaraki, Japan). Procedures involving the care and handling of animals were reviewed and approved by the Institutional Animal Care and Use Committee. The experimental protocol was designed to comply with the Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies (Federal Institute for Risk Assessment, 2009). Male Crl:CD(SD) rats purchased from Charles River Laboratories Japan, Inc. (Kanagawa, Japan) were used in this study. Animals weighed between 197 and 249 g and were seven weeks old at administration. They were housed in a facility with 12 hr light/dark cycles and were fed a CR-LPF diet (Oriental Yeast, Co. Ltd., Tokyo, Japan). Three rats were used for each time point per chemical (a total of 189 rats were used). Male cynomolgus monkeys were purchased from Japan Laboratory Animals, Inc. (Tokyo, Japan). Animals weighed between 3.49 and 5.69 kg and were three to six years old at administration. The mon- keys were housed in a facility with 12 hr light/dark cycles and fed CMK-2 diet (CLEA Japan, Inc., Tokyo, Japan). Three monkeys were used for each dose per chemical (a total of 18 monkeys were used). The test formulations were orally administrated to animals by gavage. GL (2.24, 7.46, 22.4 or 341 mg/5 ml/kg) or an equimolar amount of G (0.492, 1.64, 4.92 or 75 mg/ 5 ml/kg) was administered under non-fasting conditions. GL and G were dissolved in olive-oil and water for injection, respectively. Separately, G dissolved in water for injection was administered as a single intravenous injection via the tail vein in rats or the saphenous vein in monkeys at a dose of 75 mg/2 ml/kg. Individual dose volumes were calculated based on body weight, measured just before the administration.
Dosage levels
The proportion of total GEs in DAG oil was determined to be 373 μg/g (as GL) at the start of this investigation. The possible daily dietary exposure to G for humans who ingest DAG oil, assuming 10 g of daily consumption and 50 kg body weight, was calculated to be 16.4 μg/kg (74.6 μg/kg as GL) based on the worst case scenario of 1) complete release of G from GEs during digestion, and 2) full systemic availability of the released G.
The highest dose (75 mg/kg) of G used in the present study corresponded to that used in the NTP rat oncology study with G which was defined as the maximal tolerated dose for two year oral gavage based on a preliminary 13 week toxicity study (National Toxicology Program, 1990 ). This dosage level was too high (4571-fold) compared to the possible daily dietary exposure level of DAG oil. It has been reported that other edible oils mainly consist of triacylglycerols containing GEs at approximately 12 -46-fold lower levels than DAG oil (Masukawa et al., 2010) . Thus, the gap would be greater.
Therefore, to analyze the kinetics of GL or G plasma concentrations closer to practical dosage levels, we administered GL or G by gavage to both species at three lower doses and quantified G in the plasma at the same times specified below. The dosage levels were 2.24, 7.46, and 22.4 mg/kg for GL and 0.492, 1.64, 4.92 mg/kg for G, which corresponded to 30-, 100-and 300-times the possible human daily dietary exposure level.
Blood sampling and treatment of plasma sample
Blood samples were collected from rats under ether via the abdominal aorta with a heparinized syringe at specified time points (0.08, 0.25, 0.50, 1, 2, 4, 8 and 24 hr after administration). Blood samples were collected from monkeys without anesthesia via the cephalic vein by heparinized syringe at specified time points (before administration and 0. 08, 0.25, 0.50, 1, 2, 4, 8, 24, 48, 72 and 96 hr after administration). Blood samples were centrifuged immediately after collection. The plasma was mixed with acetonitrile (four times the volume of plasma). After the mixture was centrifuged, the supernatant (TK sample) was collected and stored at about -80°C.
GL analysis
The quantification of GL in plasma was performed with an LC-MS/MS system comprised of an Agilent 1100 Series LC system connected to an AB SCIEX API4000 triple quadrupole mass spectrometer. The following procedure was used to quantify GL (at a level of 5 ng/ml or more) in plasma samples.
After 225 μl of a TK sample was mixed with 50 μl of 500 ng/ml IS-1 solution in acetonitrile, the mixture was evaporated to dryness at room temperature using a nitrogen stream. The dried residue was dissolved in 100 μl methanol/2-propanol (1:1 by vol). The solutions were filtered, and the filtrates were subjected to LC-MS/MS.
The LC supported an XBridge TM C18 column 4.6 mm I.D. x 150 mm, 5 μm (Waters). The binary pump was connected to mobile phases A (acetonitrile/methanol/water = 3:3:1 by vol) and B (acetonitrile/methanol = 4: 1 by vol) that were consecutively time programmed as follows: A 98% (B 2%) at 0.0 min, a linear gradient of A 98% to 0% (B 2% to 100%) between 0.0 and 7.0 min at a flow rate of 1,500 μl/min, an isocratic elution of A 0% (B 100%) from 7.0 to 12.0 min at a flow rate of 1,500 μl/min, and finally an isocratic elution of A 98% (B 2%) from 12.1 to 15.0 min at a flow rate of 2,000 μl/min (a total run time of 15.0 min). The column effluent was diverted to waste from 0 to 3 min and from 9 to 15 min after sample injection. The column temperature was maintained at 40°C. The injection volume was 10 μl in all experiments. The API4000 mass spectrometer was operated with the following settings: Ion source, heated nebulizer; scan type, Q1 multiple ions; polarity, positive; curtain gas, 40 units; ion source gas, 35 units; source heater temperature, 450°C; nebulizer current, 5.0 μA; monitoring ions, each of the protonated molecular ions [M + H]+ was used: m/z 337.30 for GL and m/z 327.50 for IS-1; and declustering voltage, 96 V for GL and 91 V for IS-1. Quantitative MS analysis was performed using Analyst software (Ver. 1.4.1, Applied Biosystems/MDS Analytical Technologies Instruments).
G analysis
The quantification of G in plasma was performed with a GC-MS system comprised of an Agilent HP6890 Series GC System connected to an Agilent HP5973N Mass Spec-trometer. The following procedure was used, at a level of 0.2 μg/ml or more, in plasma samples.
After 225 μl of a TK sample was mixed with 50 μl of 10 μg/ml IS-2 solution in acetonitrile, the mixtures were loaded onto an Oasis ® HLB μElution Plate that was preequilibrated with 200 μl of acetonitrile. The passed solutions were subjected to GC-MS. In the GC instrument, a DB-WAX column (0.25 mm I.D. x 30 m, Film Thickness 0.25 μm) (Agilent Technologies) was used with the following settings: column temperature, 70°C (2 min) -40°C/min -120°C (4 min) -40°C/min -230°C (5 min); carrier gas, He; flow rate, 1.0 ml/min; injection mode, pulsed splitless; inlet temperature, 140°C; pulse pressure, 28.3 psi; pulse time, 1.50 min; purge time, 1.51 min (flow rate = 100 ml/min); gas saver, 2.00 min (flow rate = 20.0 ml/min); and interface temperature, 200°C. The injection volume was 2 μl in all experiments. The HP5973N Mass Spectrometer was operated in EI mode (70 eV) with the following settings: Ion source temperature, 230°C; quadrupole temperature, 150°C; and monitoring ions, m/z 44 for GL and m/z 70 for IS-2. Quantitative MS analysis was performed using MSD ChemStation software (D.03.00.611, Agilent Technologies).
Toxicokinetics parameters
As for plasma G concentrations, the following parameters were determined using noncompartmental methods for analysis with WinNonlin Professional (Version 5.2.1 Pharsight Corporation) and Phoenix WinNonlin (Version 6.1 Pharsight Corporation). Actual blood sampling times were used in the model. AUC (0-t) (hr·μg/ml) is the area under the plasma concentration-time curve up to the last observed quantifiable concentration time. C 0 (μg/ml) is the initial plasma concentration. C max (μg/ml) is a maximum plasma concentration over the entire sampling phase, directly obtained from the experimental data of plasma concentration versus time curves. T max (hr) is the time needed to attain C max . T 1/2 (hr) is an apparent elimination half-life. In monkeys, these parameters are presented as average values for each individual animal. In both species, oral bioavailability of G was calculated by dividing AUC (0-t) of oral G administration by that of intravenous G administration.
RESULTS
GL was not detected in any of the samples from either species. In contrast, despite the lower sensitivity for G (0.2 μg/ml) than GL (5 ng/ml), G was detected in the plasma of animals administered G and also in those administered GL. The plasma concentration-time profiles of G in the two species are illustrated (Figs. 2A, B) and TK parameters are shown in Table 1 .
In rats, oral administration of G at 75 mg/kg increased the plasma concentration of G after five min. Concentration peaked after 15 min and declined to less than the detection limit (0.2 μg/ml) after 24 hr. A comparable profile was observed for GL administration. In monkeys, after oral G administration, the plasma concentration of G had also increased after five min, peaked around one hr, and declined below the limit of detection limit at eight to 24 hr. The C max and AUC values were 3.9-fold and 2.0-fold lower, respectively, in monkeys than in rats. After oral GL administration, the C max and AUC values decreased further; specifically, they were 18-fold and 4.6-fold lower in monkeys than in rats.
In parallel, rats and monkeys were intravenously administered G at the same dose (75 mg/kg) as the gavage. In both species, plasma concentration was highest at C 0 and declined linearly to B.L.Q after four hr. The plasma concentration-time profiles and TK parameters were comparable in the two species ( Figs. 2A, B ; Table 1 ). Oral bioavailability of G was 68.8% in rats, and 34.3% in monkeys. Table 2 shows the TK parameters when G or GL was administered by gavage at the lower three doses. Since no GL was quantified in the plasma of either species after administration of GL or G by oral gavage at the highest dose, no quantification of GL in the plasma was carried out at the lower doses.
In rats, comparable G plasma concentration-time profiles were observed after administration of GL or G at the 300-fold (22.4 and 4.92 mg/kg, respectively) and 100-fold (7.46 and 1.64 mg/kg, respectively) exposure levels. C max values of G after GL administration were lower compared to those after G administration. G was not quantifiable at the lowest dose (30-fold exposure level). In monkeys, G was no longer quantifiable after GL administration at the three lower doses. G administration at the 300-fold exposure level (4.92 mg/kg) resulted in AUC and C max values that were 4.2-fold and 4.7-fold lower in monkeys than in rats. G was not quantifiable at the lower two G doses (30-fold and 100-fold exposure levels).
DISCUSSION
G, but not GL, was quantified in the plasma of both rats and monkeys regardless of GL or G administration, suggesting that GEs are not systematically available. To the best of our knowledge, this is the first report demonstrating no systemic availability of GE, when administered orally. Although GL investigated in the present study might not reflect all GEs, characterizing G exposure may be necessary if the health risk of GEs contained in foods is to be addressed.
In the rat study, oral G administration resulted in the rapid appearance and elimination of G in the plasma. Calculated oral bioavailability was approximately 70%, which is consistent with the previous rat in vivo kinetics study using 14 C labeled-G reported by Nomeir et al. (1995) . According to their calculation, approximately 87-92% of the dose was absorbed from the gastrointestinal tract of the rat. Since we measured free G in the plasma, the difference in the absorbed amount of G can be explained by G bound to proteins in the blood or by G metabolites after absorption. Oral GL administration also resulted in a similar G plasma concentration-time course. Indeed, there are no remarkable differences in TK parameters between G and GL administration (Table 1) , indicating that GL is rapidly and fully converted to G in the rat gastrointestinal tract and absorbed into the circulation.
In the monkey study, G administration also resulted in the rapid appearance and elimination of G in the plasma, but more slowly and to a lesser extent than observed in the rats. G was quantifiable in plasma after oral GL administration only when the highest dose available (341 mg/kg) was given. Even then, the AUC and C max values of G were remarkably lower in monkeys than in rats.
Since TK parameters were comparable when administrated intravenously, the kinetics of G after absorbance into the circulation is considered essentially the same in the two species. Therefore, species variations must be attributable to differences in the gastrointestinal environment and the process of absorption or metabolism of G and GEs before entering the circulation. The following factors may account for the difference: 1) lipase activity; 2) the physicochemical gastrointestinal environment, particularly pH; and 3) detoxification of G by metabolic enzymes.
In general, the hydrolysis of fatty acid esters is catalyzed by lipase. GEs are also assumed to form G via lipase hydrolysis. Marked differences in the activity and localization of lipase between rodents and primates have been reported. DeNigris et al. (1988) demonstrated that mice and rats have strong lingual lipase activity and trace gastric lipase activity, whereas these activities are reversed in baboons and humans. Levels of lingual lipase activity in rodents (rat, 824 ± 224; mouse, 250 ± 20 U/g tissue wet weight) were greater than those of gastric lipase in primates (baboon, 109 ± 29; human, 118 ± 8.8 U/g tissue wet weight) when triolein was used as a substrate. In our experiments, GL was directly administered to rat stomachs by gavage. Nonetheless, lingual lipase is reportedly secreted continuously and accumulates in the stomach between meals, where it hydrolyzes fat even under acidic conditions. Species differences in activity and specificity of lipase toward GEs in the gastrointestinal tract may play a key role in determining the extent to which G is released from GEs during digestion. The gastric environment also differs between rodents and primates. In particular, the pH of the stomach is higher in rodents than in primates. Stomach pH ranges from 3.8 to 5.0 in rats, 2.8 to 4.8 in monkeys, and from 1.0 to 3.0 in humans, though it is influenced by the food matrix, chyme composition, etc. (Kararli, 1995) . Because of the reactivity of epoxides, in solution G can undergo several spontaneous reactions involving nucleophilic attack at the alpha or beta carbon; at neutral pH and 37°C, G slowly hydrolyzes to glycerol; in 0.1 M hydrochloric acid, the hydrolysis to glycerol (97.2%) and alpha-chlorohydrin Dose, C 0 , C max , T max , T 1/2 and AUC (0-t) are expressed in mg/kg, μg/ml, hr, hr and hr·μg/ml. -: not calculated. Corresponds to an equimolar amount of GL. Dose, C max , T max , T 1/2 and AUC (0-t) were expressed in mg/kg, μg/ml, hr, hr and hr·μg/ml. B.L.Q.: below the lower limit of quantification (0.2 μg/ml); -: not calculated.
(3-chloro-1,2-propanediol) (2.8%) occurs rapidly, with a half-life of ten minutes (National Toxicology Program, 1990) . Because monkeys have a lower stomach pH compared to rats, the majority of G formed in the gastric tract may hydrolyze to glycerol before absorption, resulting in lower G concentration in the plasma of monkeys than in rats. Detoxification of epoxide compounds such as glycidamide (Gargas et al., 2009) , cyanoethylene oxide (Kedderis and Batra, 1993; Kedderis et al., 1995) , diepoxybutane , epoxybutene (Csanády et al., 1992) and styrene oxide (Mendrala et al., 1993 ) is achieved by EH or by conjugation with glutathione, which is partially mediated by GST. Higher EH activity and lower GST activity in humans than in rodents has been observed with these epoxides. As G metabolites mediated by EH or GSH were identified in in vivo and in vitro studies, these enzymes are likely involved in the detoxification of G and GEs and may affect species differences on systemic exposure to G. However, the liver is the key organ where these enzymes work to detoxify G (or GEs, if any) and is involved not only in the first-pass effect during absorption, but also in the metabolism of blood components. However, since G kinetics were similar after absorption into the circulation, the effect of these enzymes on species differences might be limited.
Further research should address involvement of these factors on species differences in the TK of G and GEs. Of course, there are still differences in TK between monkeys and humans. Observations in monkeys may not necessarily reflect human physiology. Nevertheless, another study addressed long-term human exposure to G by measuring levels of the G-hemoglobin (Hb) adduct. It demonstrated that there was no difference in the amount of G-Hb adduct between people who had ingested DAG oil containing GEs and non-DAG oil users (Honda et al., 2011) . This result suggested that there is no increased exposure to G in DAG oil users. Even if the GEs in DAG oil were converted to G in the body, extra exposure to G had minimal impact. The present study may also substantiate this earlier conclusion.
In summary, the present study addressed the TK of GL, as a representative GE found in edible oils, and G between rodents (rats) and primates (monkeys). The results indicate that GEs are probably not systematically available in the two species, and that monkeys are less likely to be exposed to G formed from ingested GEs than rats. Accounting for species differences would be necessary before human risk assessments of GEs can be performed.
